Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (163)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Hypothalamic free fatty acid receptor-1 regulates whole-body energy balance

    Molecular Metabolism, Vol. 79

  3. Inflammatory bowel disease induces pathological α-synuclein aggregation in the human gut and brain

    Neuropathology and Applied Neurobiology, Vol. 50, Núm. 1

  4. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

  5. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 760-776

  6. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

    European Archives of Psychiatry and Clinical Neuroscience

  4. Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship

    Journal of Clinical Periodontology, Vol. 50, Núm. 11, pp. 1444-1454

  5. Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner

    Nature Communications, Vol. 14, Núm. 1

  6. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  7. Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 861-871

  8. Combined cell-based therapy strategies for the treatment of Parkinson's disease: Focus on mesenchymal stromal cells

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 478-484

  9. Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders

    Brain Sciences, Vol. 13, Núm. 2

  10. Depressive Symptoms and Their Impact on Quality of Life in Parkinson’s Disease: An Exploratory Network Analysis Approach

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  11. Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

    Movement Disorders Clinical Practice, Vol. 10, Núm. 4, pp. 586-595

  12. Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

    Antioxidants, Vol. 12, Núm. 12

  13. Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

    Antioxidants, Vol. 12, Núm. 7

  14. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014